SARS-CoV-2-triggered activation of interferon signaling functionally restricts viral replication but is not sufficient to completely defend the infection, whereas therapeutic combining indomethacin with IFN-α treatment harnesses this innate defense mechanism. This evidence concerns the gene IFNA1 and infection.